29 Oct 2019
Vienna, Austria and Oslo, Norway, October 29, 2019 – Themis Bioscience and CEPI – the Coalition for Epidemic Preparedness Innovations – announced today the first administration to healthy volunteers in a Phase 1 clinical trial with Themis’ vaccine candidate against Lassa fever. The MV-LASV Lassa fever vaccine candidate, is based on Themis’ proprietary measles vector platform and exclusively-licensed discoveries made at Institut Pasteur. The MV-LASV Lassa fever vaccine program is funded through a global partnership with CEPI that will support the candidate vaccine’s development up to the end of Phase 2, which is designed to provide clinical safety and immunological data. The investment, which was the first in CEPI’s portfolio, will also help establish investigational stockpiles of Themis’ vaccine candidate that will be ready for clinical efficacy trial testing during outbreaks.
MD, CEO of Themis
Director of Vaccine Research and Development, CEPI
The MV-LASV vaccine candidate is a recombinant, live attenuated, viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection. The Phase 1 trial with MV-LASV is a randomized, placebo-controlled, dose-finding study in 60 healthy adult participants to investigate the safety, tolerability and immunogenicity of MV-LASV after administration of two different dose levels. The study, sponsored and led by Themis, is being conducted by the Centre for the Evaluation of Vaccination in Antwerp, Belgium, under the direction of Pierre Van Damme, MD, PhD, Professor at the University of Antwerp, Faculty of Medicine and Health Sciences. More information about the trial can be obtained using the ClinicalTrials.gov Identifier, NCT04055454.
About Lassa Fever
Lassa fever is also known as Lassa hemorrhagic fever. The Lassa virus is transferred to humans via contact with food or household items that are contaminated with rat urine or feces, most commonly by the infected Mastomys rodent. The virus can spread from person-to-person via bodily fluids and causes a range of symptoms including vomiting, swelling of the face, bleeding, and pain in the chest, back and abdomen. There is currently no vaccine that protects against Lassa fever.
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations launched in Davos in 2017 to develop vaccines to stop future epidemics. CEPI has received multi-year funding from Norway, Germany, Japan, Canada, Australia, and the Bill & Melinda Gates Foundation, and Wellcome. CEPI has also received single-year investments from the Governments of Belgium and the United Kingdom. The European Union provides financial support for relevant projects through their Horizon 2020 programme as well as through the European and Developing Countries Clinical Trials Partnership. CEPI has reached over US$750 million of its $1 billion funding target. Since its launch in January 2017, CEPI has announced four calls for proposals. The first call was for candidate vaccines against Lassa virus, Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Nipah virus. The second call was for the development of platforms that can be used for rapid vaccine development against unknown pathogens. The third call was for candidate vaccines against Chikungunya and Rift Valley fever viruses. The fourth call is for the development of platform technologies to develop vaccines and other immunoprophylactics to rapidly respond to outbreaks of unknown pathogens. To date, CEPI has committed to investing over $456 million in vaccine development. This includes 19 vaccine candidates against its priority pathogens (six against Lassa virus, five against MERS-CoV, four against Nipah virus, two against Chikungunya, two against Rift Valley fever) and three vaccine platforms to develop vaccines against Disease X. To assess the effectiveness of these platforms 7 additional vaccine candidates are being developed (two against influenza, one against Marburg virus, two against Rabies virus, one against Respiratory Syncytial Virus, and one against yellow fever).
Themis is developing immunomodulation therapies for infectious diseases and cancer. Through advanced understanding of immune system mechanisms, the Company has built a sophisticated and versatile technology platform for the discovery, development and production of vaccines as well as other immune system activation approaches. Initially focused on preventing infectious diseases, Themis has demonstrated the potential of its versatile platform through the rapid and successful completion of Phase 2 and near-term entry into Phase 3 clinical development for a vaccine against Chikungunya, a debilitating disease with global outbreak potential. Funded to date by leading venture capital firms, Themis has also gained prestigious non-dilutive funding for emerging infectious disease indications. The Company will apply its platform and commercial manufacturing capabilities to diseases with high market potential both alone and for its partners. For more information, visit http://www.themisbio.com.
Phone: +44(0)7891249190 | Email: [email protected]
Phone: +44(0)7917030828 | Email: [email protected]
Dr. Erich Tauber, CEO
Phone: +43 1 236 7151 | [email protected]
Media requests for Themis:
Dr. Stephanie May or Dr. Jacob Verghese
Phone: +49 89 2388 7730 or +49 171 185 56 82 | [email protected]
Image Caption and Credit: Syringe and medicine vial on blue background, Shutterstock